Module 1: Regulatory Considerations for Specialty Oncology Biotherapeutics
Recorded On: 05/04/2023
There is more than one regulatory guideline that needs to be taken into consideration depending on the therapeutic modality of a biotherapeutic being developed for oncology indications. Protein-based biotherapeutics generally fall under one set of regulatory guidelines, while cell and gene therapy products fall under a different set. There are several key differences in the regulatory requirements for oncology versus nononcology indications, biotherapeutics versus small molecules, and protein biotherapeutics vs cell and gene therapies. This presentation will give an overview of the primary regulatory guidelines for the different modalities as well as highlight the similarities and differences in approaches to developing a nonclinical strategy to fulfill regulatory expectations for each type of modality. In the last few years, non-human primates (NHPs) have been in high demand, and a critical shortage of animals has developed worldwide. Considerations around the use of non-human primates (NHPs) will be discussed including: 1) if certain types NHP studies are always needed; 2) strategies that include not conducting toxicity studies in NHPs if rodents are pharmacologically relevant, and development programs where there are no pharmacologically relevant species, including NHPs.
Marque Todd, DVM, DABT
Consultant
Renaissance Consulting
Dr. Marque Todd is a board-certified regulatory toxicology expert. Dr. Todd trained as a veterinarian and completed post-doctoral work in molecular immunology and cancer biology. She has more than 25 years of experience working in the biopharmaceutical industry. Dr. Todd has extensive nonclinical development experience with a variety of biologic modalities including monoclonal antibodies, bi-specific antibodies, Fc and other fusion proteins, antibody-drug conjugates, cytokines/interleukins, protein replacement therapies, nanoparticles, cell therapies, oncolytic viruses, and therapeutic vaccines. Dr. Todd has been involved in the preparation and submission of nonclinical sections of early and late-stage regulatory documents including INDs and BLAs/NDAs and has participated in numerous successful health authority meetings.
Dr. Todd is currently a regulatory toxicology consultant to several large, mid-size and small biopharma companies. Prior to becoming an independent consultant, Dr. Todd was a Research Fellow at Pfizer and served as a Principal Scientist at Amgen and Chiron. Dr. Todd also served as an Adjunct Professor with the University of California San Diego Extension, where she co-taught a course on nonclinical toxicology and drug development with sessions focused on the nonclinical development of biotherapeutics and oncology products.